Table 3. Mean changes in laboratory values from baseline to the end of ipragliflozin treatment.
| Placebo | Ipragliflozin | ||||
|---|---|---|---|---|---|
| 12.5 mg | 25 mg | 50 mg | 100 mg | ||
| Hematocrit (%) | −0.08 ± 2.61 | 1.47 ± 1.95** | 1.49 ± 2.09** | 1.98 ± 2.09** | 1.98 ± 1.90** |
| AST (IU/L) | 1.6 ± 12.8 | −0.6 ± 6.3 | −1.3 ± 11.1 | −1.1 ± 5.2 | −1.8 ± 11.0 |
| ALT (IU/L) | 0.0 ± 7.3 | −1.9 ± 8.5 | −5.2 ± 11.3* | −3.9 ± 9.8* | −5.8 ± 10.8** |
| BUN (mg/dL) | −0.3 ± 3.5 | 1.3 ± 2.8* | 1.0 ± 3.3* | 2.2 ± 3.3** | 1.8 ± 3.5** |
| sCr (mg/dL) | −0.02 ± 0.07 | −0.01 ± 0.06 | −0.01 ± 0.05 | 0.00 ± 0.05* | 0.01 ± 0.06* |
| Uric acid (mg/dL) | −0.04 ± 0.64 | −0.05 ± 0.63 | −0.39 ± 0.73 | −0.30 ± 0.87 | −0.13 ± 0.76 |
| uOsm (mOsm/L) | −4 ± 303 | 123 ± 269 | 51 ± 250 | 146 ± 242* | 165 ± 273** |
| Urinary pH | 0.04 ± 0.67 | −0.23 ± 0.67 | −0.34 ± 0.58** | −0.32 ± 0.55** | −0.39 ± 0.65** |
| Serum electrolytes | |||||
| P (mg/dL) | −0.03 ± 0.37 | 0.05 ± 0.32 | 0.10 ± 0.39* | 0.13 ± 0.39* | 0.18 ± 0.41* |
| Mg (mg/dL) | −0.03 ± 0.14 | 0.04 ± 0.13* | 0.08 ± 0.13** | 0.09 ± 0.13** | 0.12 ± 0.13** |
| Urinary electrolytes | |||||
| Mg (mg/g Cr) | 1.4 ± 27.4 | 13.5 ± 24.0* | 14.9 ± 27.9* | 12.9 ± 20.7* | 11.9 ± 30.4* |
Each value represents the mean ± standard deviation. *P < 0.05 and **P < 0.001 (compared with placebo by t‐test). ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Cr, creatinine; Mg, magnesium; P, phosphorus; sCr, serum creatinine; uOsm, urinary osmolarity.